- Home
- ICLR
ICLR
ICON plc
as 12-20-2024 4:00pm EST
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
| Founded: | 1990 | Country: | Ireland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 17.2B | IPO Year: | 1998 |
| Target Price: | $286.67 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 8.99 | EPS Growth: | 44.49 |
| 52 Week Low/High: | $183.38 - $347.72 | Next Earning Date: | 02-19-2025 |
| Revenue: | $8,306,823,000 | Revenue Growth: | 3.63% |
| Revenue Growth (this year): | 3.96% | Revenue Growth (next year): | 2.88% |
Latest ICON plc News
ICLR Breaking Stock News: Dive into ICLR Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
ICON Announces Appointment of Chief Operating Officer
Simply Wall St.
9 days ago
Are ICON Public Limited Company's (NASDAQ:ICLR) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Insider Monkey
12 days ago
ICON Public Limited Company (ICLR) Fell on Reduced Guidance
Insider Monkey
16 days ago
ICON Public Limited Company (ICLR) Fell Along with Peers
Business Wire
16 days ago
ICON Survey Highlights Sustained Investment in AI and Digital R&D Innovation, Tempered by Siloed Adoption
Zacks
a month ago
Icon PLC (ICLR) Down 4.1% Since Last Earnings Report: Can It Rebound?
Insider Monkey
a month ago
Should You Retain Your Conviction in Icon Plc (ICLR)?
TipRanks
a month ago
Baird cuts Icon target, names ‘Bullish Fresh Pick’
Compare ICLR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ICLR ICON plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.